An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus

被引：0
|
作者：
RA Eisenberg
S Khan
J Stansberry
D Tsai
S Kolasinski
E Rieder
B Kotzin
RJ Looney
C Strieber
D Albert
机构：
[1] University of Pennsylvania,Division of Rheumatology, Department of Medicine
[2] University of Pennsylvania,Division of Hematology
[3] University of Colorado,Oncology, Department of Medicine
[4] University of Rochester,Division of Clinical Immunology, Department of Medicine
[5] University of Colorado,Division of Rheumatology, Department of Medicine
来源：
Arthritis Res Ther | / 6卷 / Suppl 3期
关键词：
Systemic Lupus Erythematosus; Systemic Lupus Erythematosus Patient; Tetanus; Mycophenolate Mofetil; Tetanus Toxoid;
D O I：
10.1186/ar1407
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Toxicity and efficacy of the anti-CD20 antibody rituximab (Rituxan™) in patients with B-cell chronic lymphocytic leukemia:: A phase I/II study.
    Winkler, U
    Schulz, HR
    Jensen, M
    Manzke, O
    Rüdiger, T
    Müller-Hermelink, KH
    Diehl, V
    Engert, A
    [J]. BLOOD, 1999, 94 (10) : 312A - 312A
  • [22] Enhanced anti-B-cell tumor effects with anti-CD20 superantibody
    Zhao, YF
    Lou, DY
    Burke, J
    Kohler, H
    [J]. JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01): : 57 - 62
  • [23] A pilot study of rituximab (anti-CD20) for refractory systemic lupus erythematosus: Relevance of quantity and quality reduction of B cells to clinical efficacy.
    Tanaka, Y
    Tokunaga, M
    Fujii, K
    Nawata, M
    Tsujimura, S
    Nakayamada, S
    Saito, K
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S414 - S414
  • [24] Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus
    Chehab, G.
    Sander, O.
    Fischer-Betz, R.
    Schneider, M.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 (04): : 328 - +
  • [25] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
    Korhonen, Riku
    Moilanen, Eeva
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21
  • [26] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [27] Enhanced anti-B-cell tumor effects with anti-CD20 superantibody - Comments
    Reisfeld, RA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01): : 62 - 62
  • [28] Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus
    Perrotta, S
    Locatelli, F
    La Manna, A
    Cennamo, L
    De Stefano, P
    Nobili, B
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) : 465 - 467
  • [29] Anti-CD20 Antibody Therapy for B-Cell Lymphomas
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    Zent, Clive S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (09): : 876 - 877
  • [30] Prolonged Effects of Short-Term Anti-CD20 B Cell Depletion Therapy in Murine Systemic Lupus Erythematosus
    Bekar, Kai W.
    Owen, Teresa
    Dunn, Robert
    Ichikawa, Travis
    Wang, Wensheng
    Wang, Roger
    Barnard, Jennifer
    Brady, Sean
    Nevarez, Sarah
    Goldman, Bruce I.
    Kehry, Marilyn
    Anolik, Jennifer H.
    [J]. ARTHRITIS AND RHEUMATISM, 2010, 62 (08): : 2443 - 2457
12345